Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2

作者：

Zhu, Viola Weijia

Bestvina, Christine M.

Lopes, Gilberto

Hamm, John Turner

Johnson, Melissa Lynne

Lammers, Philip Edward

Le, Xiuning

Marathe, Omkar

Raez, Luis E.

Rao, Suman

Sabari, Joshua K.

Scheff, Ronald J.

Tapan, Umit

Thompson, Jonathan Robert

Karachaliou, Niki

Ellers-Lenz, Barbara

Brutlach, Sabine

Smit, Egbert F.

Wu, Yi-Long

机构：

[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[4] Norton Canc Inst PARENT, Louisville, KY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Baptist Canc Ctr, Memphis, TN USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Innovat Clin Res Inst, Anaheim, CA USA

[9] Mem Healthcare Syst, Hollywood, FL USA

[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA

[11] NYU Langone Clin Canc Ctr, New York, NY USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Darmstadt, Germany

[18] Netherlands Canc Inst, Amsterdam, Netherlands

[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9136

引用

页数：3

共 50 条

[41] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Elghawy, Omar
Barsouk, Adam
Reed-Guy, Lauren
Stalker, Margaret
Sussman, Jonathan
Robinson, Kyle
Kosteva, John
Singh, Aditi
Cohen, Roger B.
Langer, Corey
Ciunci, Christine
D'Avella, Christopher
Sun, Lova
Marmarelis, Melina E.
Aggarwal, Charu
CLINICAL LUNG CANCER, 2025, 26 (02)
[42] Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
Choudhury, Noura J.
Marra, Antonio
Yang, Soo-Ryum
Falcon, Christina J.
Heller, Glenn
Kris, Mark G.
Reis-Filho, Jorge S.
Riely, Gregory J.
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[43] Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
Park, K.
Zhou, J.
Kim, D-W.
Ahmad, A. R.
Soo, R. A.
Bruns, R.
Straub, J.
Johne, A.
Scheele, J.
Yang, J. C-H.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30
[44] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
Oxnard, Geoffrey R.
Cantarini, Mireille
Frewer, Paul
Hawkins, George
Peters, Jane
Howarth, Paul
Ahmed, Ghada F.
Sahota, Tarjinder
Hartmaier, Ryan
Li-Sucholeiki, Xiaocheng
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] Afatinib plus bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial
Kobayashi, Nobuaki
Hashimoto, Hisashi
Kamimaki, Chisato
Nagasawa, Ryo
Tanaka, Katsushi
Kubo, Sousuke
Katakura, Seigo
Chen, Hao
Hirama, Nobuyuki
Ushio, Ryota
Aoki, Ayako
Nakashima, Kentaro
Teranishi, Shuhei
Manabe, Saki
Watanabe, Hiroki
Horita, Nobuyuki
Watanabe, Keisuke
Hara, Yu
Yamamoto, Masaki
Kudo, Makoto
Piao, Hongmei
Kaneko, Takeshi
THORACIC CANCER, 2020, 11 (08) : 2125 - 2129
[46] Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
Minari, Roberta
Bordi, Paola
La Monica, Silvia
Squadrilli, Anna
Leonetti, Alessandro
Bottarelli, Lorena
Azzoni, Cinzia
Lagrasta, Costanza Anna Maria
Gnetti, Letizia
Campanini, Nicoletta
Petronini, Pier Giorgio
Alfieri, Roberta
Tiseo, Marcello
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E89 - E91
[47] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
Hata, Akito
Katakami, Nobuyuki
Takase, Naoto
Kibata, Kayoko
Yamanaka, Yuta
Tamiya, Motohiro
Mori, Masahide
Kijima, Takashi
Morita, Satoshi
Sakai, Kazuko
Nishio, Kazuto
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
Cho, Byoung Chul
Felip, Enriqueta
Hayashi, Hidetoshi
Thomas, Michael
Lu, Shun
Besse, Benjamin
Sun, Tao
Martinez, Melissa
Sethi, Seema N.
Shreeve, S. Martin
Spira, Alexander, I
FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
[49] Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Besse, B.
Lee, S-H.
Lu, S.
Stroyakovskiy, D.
Yazici, O.
Rodriguez Cid, J. R.
Hayashi, H.
Nguyen, D.
Yang, J. C-H.
Gottfried, M.
Gelatti, A. C.
Owen, S.
Ou, S-H. I.
Ennis, M.
Sethi, S.
Bauml, J. M.
Zhang, J.
Curtin, J. C.
Cho, B. C.
ANNALS OF ONCOLOGY, 2024, 35 : 1245 - 1246
[50] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
Huang, M. J.
Yu, M.
Gong, Y. L.
Li, Y. Y.
Liu, Y. M.
Peng, F.
Yu, Y.
Xiu, W. G.
Wang, Y. S.
Zou, B. W.
Fan, H.
Zhong, L. Q.
Liu, T. Q.
Wang, X. F.
Xu, Y.
Zhou, L.
Lu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S146

← 1 2 3 4 5 →